Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 28, 2025 | (Q2)Jun 29, 2025 | (Q1)Mar 30, 2025 | (FY)Dec 29, 2024 | (Q4)Dec 29, 2024 | (Q3)Sep 29, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 6.77%23.99B | 5.77%23.74B | 2.39%21.89B | 4.30%88.82B | 5.26%22.52B | 5.25%22.47B | 4.31%22.45B | 2.34%21.38B | 6.46%85.16B | 7.30%21.4B |
| Operating revenue | 6.77%23.99B | 5.77%23.74B | 2.39%21.89B | 4.30%88.82B | 5.26%22.52B | 5.25%22.47B | 4.31%22.45B | 2.34%21.38B | 6.46%85.16B | 7.30%21.4B |
| Cost of revenue | 4.88%7.3B | 11.05%7.63B | 12.99%7.36B | 3.46%27.47B | 4.85%7.13B | 5.40%6.96B | 6.30%6.87B | -2.63%6.51B | 7.96%26.55B | 11.74%6.8B |
| Gross profit | 7.62%16.69B | 3.45%16.12B | -2.26%14.54B | 4.68%61.35B | 5.45%15.39B | 5.17%15.51B | 3.46%15.58B | 4.68%14.87B | 5.80%58.61B | 5.36%14.6B |
| Operating expense | -7.19%9.49B | 4.30%9.31B | -4.21%8.24B | 11.38%39.2B | 15.63%11.55B | 19.69%10.23B | 2.55%8.92B | 8.01%8.6B | 2.37%35.2B | 0.41%9.99B |
| Selling and administrative expenses | 10.31%5.82B | 5.62%5.79B | -0.89%5.01B | 9.23%21.97B | 13.48%6.25B | 3.49%5.28B | 9.71%5.48B | 12.23%5.06B | -0.66%20.11B | -11.68%5.51B |
| -General and administrative expense | 10.31%5.82B | 5.62%5.79B | -0.89%5.01B | 9.23%21.97B | 13.48%6.25B | 3.49%5.28B | 9.71%5.48B | 12.23%5.06B | -0.66%20.11B | -11.68%5.51B |
| Research and development costs | -25.85%3.67B | 2.21%3.52B | -8.95%3.23B | 14.23%17.23B | 18.26%5.3B | 43.66%4.95B | -7.10%3.44B | 2.52%3.54B | 6.72%15.09B | 20.75%4.48B |
| Operating profit | 36.34%7.2B | 2.30%6.81B | 0.41%6.3B | -5.38%22.15B | -16.63%3.84B | -14.84%5.28B | 4.70%6.66B | 0.43%6.27B | 11.40%23.41B | 17.95%4.61B |
| Net non-operating interest income (expenses) | -118.18%-18M | -138.40%-48M | -38.76%128M | 18.00%577M | -32.08%144M | -45.60%99M | 14.68%125M | 1,592.86%209M | 128.50%489M | 175.32%212M |
| Non-operating interest income | -22.26%227M | -34.18%260M | -8.79%332M | 5.63%1.33B | -22.59%281M | -21.93%292M | 21.17%395M | 83.84%364M | 157.35%1.26B | 42.91%363M |
| Non-operating interest expense | 26.94%245M | 14.07%308M | 31.61%204M | -2.20%755M | -9.27%137M | 0.52%193M | 24.42%270M | -26.89%155M | 179.71%772M | -14.69%151M |
| Other net income (expenses) | 116.51%337M | 75.58%-264M | 360.26%7.2B | 31.32%-6.05B | -1,375.00%-59M | -75.34%-2.04B | -645.52%-1.08B | 62.99%-2.77B | -371.20%-8.8B | 97.47%-4M |
| Gain on sale of security | --400M | ---- | ---- | 50.00%-300M | -80.00%100M | ---- | ---400M | ---- | ---600M | --500M |
| Special income (charges) | 93.59%-163M | 57.08%-464M | 332.22%6.88B | 18.53%-6.85B | 57.12%-259M | -862.50%-2.54B | -341.22%-1.08B | 59.28%-2.96B | -694.14%-8.4B | -209.42%-604M |
| -Less:Restructuring and mergern&acquisition | 15.60%163M | -57.62%164M | -55.68%117M | 31.05%1.03B | -58.96%142M | -10.76%141M | 166.90%387M | 103.08%264M | 186.91%789M | 361.33%346M |
| -Less:Impairment of capital assets | ---- | ---- | ---- | -32.59%211M | ---- | ---- | ---- | ---- | -60.03%313M | ---- |
| -Less:Other special charges | ---- | -40.00%300M | -359.26%-7B | -23.29%5.6B | -50.00%100M | 2,500.00%2.4B | 400.00%500M | -61.97%2.7B | --7.3B | --200M |
| -Less:Write off | ---- | --0 | ---- | ---- | ---- | --0 | --194M | ---- | ---- | ---- |
| Other non-operating income (expenses) | -80.00%100M | -50.00%200M | 63.78%321M | 450.00%1.1B | 0.00%100M | 400.00%500M | 300.00%400M | 296.00%196M | 124.69%200M | 107.09%100M |
| Income before tax | 124.48%7.49B | 12.93%6.49B | 267.02%13.63B | 10.79%16.69B | -19.46%3.89B | -36.02%3.34B | -8.85%5.75B | 388.58%3.71B | -22.20%15.06B | 25.68%4.83B |
| Income tax | 263.51%2.34B | -10.17%954M | 473.42%2.63B | 50.98%2.62B | -34.29%456M | -29.07%644M | 14.19%1.06B | 157.66%459M | -41.92%1.74B | 13.21%694M |
| Earnings from equity interest net of tax | ||||||||||
| Net income | 91.24%5.15B | 18.16%5.54B | 237.91%11B | -59.99%14.07B | -15.26%3.43B | -89.65%2.69B | -8.90%4.69B | 4,886.76%3.26B | 95.94%35.15B | 15.03%4.05B |
| Net income continuous operations | 91.24%5.15B | 18.16%5.54B | 237.91%11B | 5.55%14.07B | -16.97%3.43B | -37.48%2.69B | -12.83%4.69B | 762.93%3.26B | -18.59%13.33B | 28.04%4.13B |
| Net income discontinuous operations | ---- | ---- | ---- | --0 | --0 | --0 | --0 | ---- | 1,289.37%21.83B | -128.33%-83M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 91.24%5.15B | 18.16%5.54B | 237.91%11B | -59.99%14.07B | -15.26%3.43B | -89.65%2.69B | -8.90%4.69B | 4,886.76%3.26B | 95.94%35.15B | 15.03%4.05B |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | 91.24%5.15B | 18.16%5.54B | 237.91%11B | -59.99%14.07B | -15.26%3.43B | -89.65%2.69B | -8.90%4.69B | 4,886.76%3.26B | 95.94%35.15B | 15.03%4.05B |
| Diluted earnings per share | 91.07%0.208 | 17.95%0.2236 | 238.52%0.4443 | -57.93%0.5677 | -15.25%0.1386 | -89.15%0.1089 | -1.51%0.1896 | 4,599.25%0.1312 | 103.22%1.3494 | 24.93%0.1635 |
| Basic earnings per share | 90.99%0.2061 | 18.65%0.2226 | 238.81%0.4414 | -57.80%0.5629 | -15.57%0.1371 | -89.13%0.1079 | -1.53%0.1876 | 4,565.92%0.1303 | 103.86%1.3338 | 25.56%0.1624 |
| Dividend per share | -0.16%0.1227 | 1.77%0.1231 | -2.51%0.115 | 314.33%0.48 | 1.98%0.1181 | 0.1229 | 0.121 | 0.118 | 0.1158 | 0.1158 |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.